
    
      This is a Phase 2, open-label exploratory study investigating the efficacy of fesoterodine
      for treatment of adult patients with spinal cord injuries (SCI) with autonomic dysreflexia
      (AD) triggered by neurogenic detrusor overactivity (NDO).
    
  